About STAAR Surgical Company - Common Stock (STAA)
Staar Surgical Company is a pioneering developer, manufacturer, and marketer of implantable miniature lenses, primarily used in vision correction procedures. Specializing in advanced ophthalmic technologies, the company focuses on innovative solutions for conditions such as myopia and presbyopia. Staar Surgical aims to enhance patient satisfaction and visual outcomes by providing high-quality, innovative products that are designed to improve the overall eye health and well-being of individuals seeking surgical options for improved eyesight. Through its commitment to research and development, the company continues to advance the field of vision correction and expand its global presence in the ophthalmic medical device market. Read More
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NYSE: ALC), STAAR’s Special Meeting of Stockholders in connection with STAAR’s merger agreement with Alcon (the “Special Meeting”), which was previously adjourned until November 6, 2025 at 8:30 a.m. Pacific Time, has been postponed until December 3, 2025 at 8:30 a.m. Pacific Time. The new record date for the Special Meeting is the close of business on October 24, 2025. Stockholders who hold shares as of the record date will be eligible to vote at the postponed Special Meeting on December 3, 2025, and STAAR will be providing a notice of the meeting and other materials to such stockholders in advance of the meeting date.
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after the decision by STAAR Surgical and Alcon Inc. (SIX/NYSE:ALC) to adjourn STAAR’s Special Meeting of Stockholders to vote on the proposed sale to Alcon on the terms announced on August 5, 2025.
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today issued the following statement regarding the agreement between STAAR and Alcon Inc. (“Alcon”) (NYSE: ALC) to postpone a shareholder vote on the proposed sale of the Company.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that STAAR and Alcon have agreed to adjourn STAAR’s Special Meeting of Stockholders (the “Special Meeting”) scheduled for October 23, 2025, in connection with STAAR’s merger agreement with Alcon. No other business will be conducted at the Special Meeting.
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), notified the Company’s Board of Directors (the “Board”) yesterday that it intends to call a Special Meeting of STAAR shareholders for the purpose of removing several directors.
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today issued the following letter to the Board of Directors of STAAR regarding Yunqi’s opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood continues to urge its fellow shareholders to vote on the GREEN Proxy Card “AGAINST” the transaction at a virtual Special Meeting of Stockholders to be held on October 23, 2025, at 8:30 a.m. (Pacific Time).
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the third quarter ended September 26, 2025. STAAR is announcing its preliminary net sales results in advance of its quarterly earnings announcement to provide all stockholders with additional information regarding third quarter net sales performance and trends in advance of the STAAR Special Meeting of Stockholders scheduled for October 23, 2025, to vote on the Alcon merger proposal.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common shares, urges its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC) on the terms announced on August 5, 2025.
STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement:
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) vote “AGAINST” the Company’s proposed acquisition by Alcon Inc. (“Alcon”) (NYSE: ALC) (the “Proposed Merger”) on the GREEN Proxy Card.
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (“SEC”) of a “supplement” to the Company’s definitive proxy statement, filed on September 16, 2025, in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood, which owns 27.5% of STAAR’s outstanding common stock, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition on the terms announced August 5, 2025.
NEW YORK, Oct. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC) on the terms announced August 5, 2025.
STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR’s pending merger with Alcon (SIX/NYSE: ALC):
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC) on the terms announced on August 5, 2025.
Defender Capital, which owns 1.5% of STAAR’s common stock, highlighted STAAR’s board of directors' rejection of Alcon's previous offer of $58 per share in cash.
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR’s merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders.
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement with respect to the flawed, misleading, and misinformed claims recently made by Broadwood Partners, L.P.:
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
